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KAJIAN TENTANG PEROXISOME PROUFERATOR-ACTIVATED 
RECEPTOR (PPAR) ALPHA DALAM GOLONGAN PESAKIT PENYAKIT 
JANTUNG ISKEMIA DAN GOLONGAN INDIVIDU YANG SIHAT 
ABSTRAK 
Penyakit jantung iskemia merupakan penyebab utama kematian dalam Malaysia 
dan juga seluruh dunia. Oleh itu, satu penanda diagnosis baru untuk mengesan 
penyakit jantung pada peringkat awal, peroxisome proliferator-activated 
receptors-alpha (PPAR-a) diperkenalkan dalam kajian ini. Tujuan kajian ini ialah 
untuk mengkaji perbezaan kandungan mRNA PPAR-a dan protein PPAR-a 
dalam pesakit jantung iskemia berbanding dengan individu yang sihat. 
Kandungan mRNA untuk gen PPAR-a dan gen Protein C-Reaktif (CRP) dikaji 
dengan cara tindak balas rantaian polimeras transkripsi balik (RT-PCR). 
Kandungan protein untuk PPAR-a dan CRP dalam kumpulan kajian ditentukan 
dengan analisis Western blot dan Enzyme linked immunosorbent assay (ELISA). 
Dalam kajian ini, kandungan mRNA dan protein untuk serum CRP didapati 
meningkat dengan signifikannya (p<0.05) dalam pesakit penyakit jantung 
iskemia. Selain itu, protein PPAR-a variasi asli (native) dan terkupas (truncated) 
didapati terkandung dalam sel darah putih manusia. Kandungan mRNA untuk 
PPAR-a variasi asli (native) dan terkupas (truncated) didapati menurun dengan 
signifikannya (p<0.05) dalam pesakit jantung iskemia. Walaubagaimanapun, 
kandungan protein PPAR-a pula didapati hampir sama (p>0.05) dalam 
kedua-dua kumpulan kajian. Kajian ini mendapati bahawa kandungan mRNA 
untuk kedua-dua PPAR-a variasi berkurangan dalam pesakit penyakit jantung 
iskemia. Kajian seterusnya akan dijalani untuk menerangkan fenomena ini. 
Dalam kajian ini, ekspresi~terlampau protein PPAR-a variasi terkupas (truncated) 
berkemungkinan terlibat dalam patogenesis penyakit jantung iskemia. 
A STUDY OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR 
(PPAR) ALPHA IN PATIENTS WITH ISCHEMIC HEART DISEASE AND 
HEALTHY VOLUNTEERS 
ABSTRACT 
Ischemic heart disease (IHD) is the most common cause of cardiovascular 
mortality in Malaysia and around the globe. New novel biomarker, Peroxisome 
Proliferator-Activated Receptors-Alpha (PPAR-a) was investigated in this study 
to give significant contribution to early detection of IHD. In this study, we 
investigated the mRNA expression and protein levels of both PPAR-a and 
C-Reactive Protein (CRP) genes in the peripheral blood of IHD patients (n=10) 
and apparently healthy volunteers (n=1 0). The mRNA levels of PPAR-a (native 
and truncated) and CRP were determined by reverse transcription-polymerase 
chain reaction. The protein expression was evaluated by Western blot and 
measured by Enzyme linked immunosorbent assay (ELISA). The CRP mRNA 
expression and serum levels increased significantly (p<0.05) in IHD patients 
compared to normal volunteers. There was presence of both native active and 
truncated inhibitory PPAR-a protein in human blood leukocytes. The mRNA 
expressions of both native and truncated variants of PPAR-a were lower (p 
<0.05) in IHD patients group than those in the normal volunteers group. 
However, there was no significant difference (p>0.05) in PPAR-a protein level 
between IHD patients and normal volunteers. These findings suggest that 
mRNA expression level of both PPAR-a variants is decreased in IHD patients. 
An over-expression of the truncated inhibitory isoform of PPAR-a protein may be 
involved in the pathogenesis of IHD. Further study will be conducted to elucidate 
this matter. 
1.0 INTRODUCTION 
Despite dramatic advances in medicine, cardiovascular disease remains a major 
healthcare problem in Malaysia and around the globe. According to World Health 
Organization (WHO, 2005), cardiovascular disease encountered 30% of the total 
death worldwide in 2005 (Figure 1.1 ). In Malaysia, cardiovascular disease is the 
leading cause of death of non-communicable diseases. It encountered 30% of 
the all deaths in Malaysia in 2002 (Figure 1.2). According to Ministry of Health 
Hospitals' Survey reported in year 2002, cardiovascular disease persistently 
accounts for 15-16% of all hospital deaths annually since 1995 to 2002. 
Furthermore, ischemic heart disease was the most common cause of 
cardiovascular mortality and accounted for 2,556 deaths in 2002 with a further 
896 deaths due to heart failure of ischemic origin in Malaysia. · 
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Figure 1.1. The main causes of death worldwide in all ages in year 2005 (WHO, 2005} 
Figure 1.2. Deaths by cause in all ages in Malaysia in year 2002. (WHO, 2002) 
Ischemic heart disease is synonymous with coronary heart disease. The term 
coronary heart disease is used to describe a disorder of the heart muscle 
resulting from narrowing of the coronary arteries. Because of the narrowing, the 
heart muscle may not receive sufficient blood. Often the blood supply is only 
insufficient when demands on the heart are increased as on exercise. This 
transient ischemia may cause a chest discomfort called angina, which 
characteristically disappears on rest. When the reduction in blood supply is so 
severe as to cause death of the muscle cells beyond obstruction, this is known 
as 'myocardial' referring to the heart muscle and 'infarction' to the death cells 
(Julian and Marley, 1991 ). 
In the vast majority of cases, coronary heart disease is the result of a process 
known as atherosclerosis (Julian and Marley, 1991). Atherosclerosis is a specific 
form of chronic inflammatory process resulting from interactions between 
plasma lipoproteins, cellular components (monocyte or macrophages, T 
lymphocytes, endothelial cells and smooth muscle cells) and the extracellular 
matrix of the arterial wall (Fan and Watanabe, 2003). The atherosclerotic plaque 
is composed of fibrous cap that covers the surface. Beneath the cap is the soft 
portion of the plaque filled with lipid-laden macrophages, oxidized low-density 
lipoprotein cholesterol and other cellular waste products possibly including 
calcium deposits. The plaque narrows the lumen of the coronary arteries, 
reduces the volume of blood that can flow through them, and leads to myocardial 
ischemia. Coronary atherosclerosis begins in early life but it required decades to 
develop mature plaques responsible for ischemic heart disease (Pasterkamp 
and Falk, 2000). Plaque formation also predisposes to thrombosis, which can 
provoke myocardial infarction. 
Biochemical markers play a vital role in the diagnosis and management of 
patients with ischemic heart disease. The World Health Organization (WHO) has 
traditionally defined myocardial infarction as requiring the presence of at least 
two of three diagnostic criteria, namely, an appropriate clinical presentation, 
typical changes in the electrocardiogram and raised "cardiac" enzymes, 
essentially total creatine kinase (CK) or its MB iso-enzyme (CK-MB) activities 
(Panteghini, 2004). Enzymatic assays for CK and lactate dehydrogenase 
catalytic activities were developed 20 years ago for the retrospective detection of 
cardiac tissue necrosis (Panteghini, 2004). In the latter part of the 20th century, 
highly sensitive and specific assays for the detection of myocardial damage, 
such as cardiac troponins have become available, assigning to the laboratory a 
pivotal role in the diagnosis and follow-up of patients with cardiac disease 
(Panteghini, 2004). The weakness for all of these biochemical markers is that 
they only can detect myocardial ischemia or IHD at later stage (necrosis stage) 
with irreversible myocyte injury which will then complicate treatment. Therefore, 
there is an urgent necessecity for the development of early markers that can 
reliably detect coronary atherosclerosis at early presentation and also detect 
myocardial ischemia in the absence of irreversible myocyte injury. 
Substantial experimental and clinical evidence links local and systemic 
inflammation to atherosclerosis (Kaperonis et a/., 2006) and supports a central 
role for inflammation in early atherogenesis, in the progression of lesions, and 
finally in the thrombotic complications of the atherosclerotic process (Libby eta/., 
2002). In the last few years, there has been an increasing interest in specific 
serum markers that could reflect the severity of systemic inflammation. 
C-reactive protein (CRP), serum amyloid A (SAA), proinflammatory cytokines 
and adhesion molecules have all been linked to increased risk of future 
cardiovascular events (Kaperonis et a/., 2006) but CRP has been the most 
widely studied and much has been written and discussed regarding its 
relationship to inflammation, coronary artery pathology and coronary disease 
outcome (Panteghini, 2004). 
CRP is an acute-phase protein synthesized by the liver in response to microbial 
infection, tissue injury, and autoimmune disorders. It has been shown to be an 
excellent predictor of future cardiovascular events in apparently healthy men and 
women due to its biological properties such as its stability, lack of diurnal 
variation and lack of influence of gender and age (Calabro eta/., 2003). CRP has 
also been found in human atherosclerotic plaques which could be the result of 
indirect deposit from circulating cells or direct production by human coronary 
artery smooth muscle cells after stimulation by inflammatory cytokines (Calabro 
et a/., 2003). In clinical laboratories, normal cut-off values of either 5 or 8 J.Jg/ml 
of serum CRP are used to assess whether the presence or absence of 
inflammation (Wu eta/., 2002). During the acute phase reaction, serum CRP 
levels often increase up to 100 or 200 IJQ/ml (Calabro eta/., 2003). However, the 
level of serum CRP that is useful for predicting cardiovascular risk is 1 to 3 J.Jg/ml 
because CRP production by human coronary artery smooth muscle cells is less 
robust than those produced by liver (Calabro eta/., 2003). In fact, patients with 
serum CRP levels more than 10 J.Jg/ml should have the test repeated at a later 
date to exclude infection, autoimmune diseases, or malignancy (Calabro eta/., 
2003). 
A multimarker paradigm using a combination of both established and new 
markers for risk assessment and clinical decision-making has the potential to 
improve substantially the outcomes in patients with acute coronary syndrome 
caused by ischemic heart disease {Morrow and Braunwald, 2003). Therefore 
there is an urgent need to search for a new and novel biomarker to give further 
significant contribution to multi-marker strategy in early diagnostic of IHD. The 
emergence of Peroxisome Proliferator-Activated Receptor Alpha (PPAR-a) as 
transcriptional regulators involved in lipid metabolism, inflammation and 
atherosclerosis has directed attention towards the advent of a new biomarker for 
early detection of IHD. 
PPAR-a activation interferes with early stage of atherosclerosis by reducing 
leukocyte adhesion to activated endothelial cells of the arterial vessel wall and 
inhibiting subsequent transendothelial leukocyte migration. Besides, PPAR-a 
activation also inhibits the formation of macrophage foam cells in the later stage 
of atherosclerosis. Furthermore it also increases the stability of atherosclerotic 
plaques and limits plaque thrombogenicity {Zandbergen and Plutzky, 2007). The 
purpose of this study is to develop and optimize methods for measurement of 
human PPAR-a in human blood sample and also to investigate the difference of 
PPAR-a level in blood sample between apparently healthy volunteers and IHD 
patient with ischemic heart disease. 
2.0 OBJECTIVE 
The objectives of this present study are: 
1. To optimize reverse transcription polymerase chain reaction (RT-PCR) 
method for measurement of human PPAR-a mRNA expression in human 
blood sample. 
2. To optimize Enzyme-linked immunosorbent assay (ELISA) method for 
measurement of human PPAR-a protein level in human blood sample. 
3. To investigate the difference of PPAR-a mRNA expression level between 
apparently healthy volunteer and IHD patient with RT-PCR. 
4. To investigate the difference of PPAR-a protein level between apparently 
healthy volunteer and IHD patient with ELISA. 
3.0 LITERATURE REVIEW 
3.1 Atherosclerosis (Underlying Cause of IHD) 
(A) History of Atherosclerosis 
In 1815, London surgeon Joseph Hodgson observed the inflammatory 
characteristics of atherosclerotic lesions. He published an important monograph 
on vascular disease, claiming that inflammation was the underlying cause of 
atherosclerosis and it is not a natural degenerative occurrence of the aging 
process. He also identified that this disease process occurred in the intima, 
between the lumen and the media of the diseased vessels (Kaperonis eta/., 
2006}. 
In 1856, Rudolf Virchow's description of the pathogenesis of atherosclerosis was 
an in-depth investigation of the histologic characteristics of the atherosclerotic 
lesion in all its stages (Heidland eta/., 2006). He was the first to coin the term of 
"endarteriitis deformans". By this he meant that the atheroma was a product of 
an inflammatory process within the intima and that the fibrous thickening evolved 
as a consequence of a reactive fibrosis induced by proliferating connective 
tissue cells within the intima (Heidland et a/., 2006). He maintained that 
mechanical forces initiated the irritative stimulus and that the endarteritis was 
part of a repair mechanism. He proposed in the same year that atherosclerosis 
was caused when plasma components elicited an inflammatory response in the 
arterial wall and resulted local intima injury (Zarifis, 2005). His theory has 
elements that are acceptable to current thinking, but it also has features that 
have been invalidated. However, suffice it to say that Virchow's concept of local 
intima injury as the initiating 11irritativen stimulus is still accepted and it has been 
extended to include other factors besides mechanical factors. His hypothesis 
formed the basis of response-to-injury hypothesis of Russel Ross more than a 
century later. 
For the major part of the 20th century, the lipid theory dominated the field of 
atherogenesis until R. Ross reopened the discussion on the inflammatory nature 
of the atherosclerosis in 1976. Ross, Glomset and Harker produced a 
response-to-injury hypothesis which postulates that the lesions of 
atherosclerosis result as a response to some form of injury to arterial endothelial 
cells. It is followed by endothelial desquamation and platelet adherence, 
aggregation, and release at the sites of exposed subendothlial connective tissue. 
These events precede the intimal smooth muscle proliferative response that is a 
prerequisite of atherosclerotic lesion formation. These studies pointed to the key 
role of the platelet in the stimulation of intimal smooth muscle proliferation that 
leads to the development of lesions of atherosclerosis (Ross eta/., 1977) 
The response-to-injury theory of atherogenesis is still valid until now with minor 
alterations. 
(B) Progression of Atherosclerosis 
Atherosclerosis involves several highly interrelated processes, including lipid 
disturbances, platelet activation, thrombosis, endothelial dysfunction, 
inflammation, oxidative stress, vascular smooth cell activation, altered matrix 
metabolism, remodeling, and genetic factors (Faxon eta/., 2004). Endothelial 
dysfunction seems to be the first step in atherogenesis and from this point on, an 
inflammatory response is triggered that leads to the development of 
atherosclerotic plaque. Endothelial dysfunction can occur in response to a 
variety of stimuli such as oxidized LDL, free radicals caused by smoking, 
hypertension, diabetes, genetic alterations, elevated plasma homocysteine 
concentrations and infectious microorganisms (Kaperonis eta/., 2006). 
Healthy endothelium, does not normally bind white blood cells. Soon after 
activation by atherogenic stimuli, many endothelial cells begin to express on 
their surface adhesion molecules (selectins, intercellular adhesion molecules 
ICAMs, vascular cell adhesion molecule VCAMs) that act as receptors for 
glycoconjugates and integrins present on monocytes and T-cells (Kaperonis et 
a/., 2006). Vascular cell adhesion molecule-1 (VCAM-1 ), intracellular adhesion 
molecule-1 (ICAM-1) and some of the CC-Chemokine Receptors (CCRs) enable 
the subsequent adherence of circulating leukocytes to the endothelium. In 
response to signals generated within the early plaque, leukocytes adhere to the 
endothelium and then migrate through the endothelium and basement 
membrane into the intima by elaborating enzymes, including locally activated 
matrix metaloproteinases (MMP) that responsible for the migration of monocytes 
into intima through degrading the connective tissue matrix (Crowther, 2005). The 
migrated leukocytes will differentiate into tissue macrophages in the presence of 
different cytokines such as Macrophage Colony Stimulating Factor (M-CSF), 
Tumor Necrosis Factor a (TNF a), Interferon y (IFNy), proinflammatory 
interleukins (e.g. lnterleukins-1 and -2; IL-1, -2) and growth factors (like 
Transforming Growth Factor J3 (TGFJ3), Platelet Derived Growth Factor (PDGF) 
and Insulin-like Growth Factor-1 (IGF-1) (Ross, 1999). M-CSF leads to the 
ingestion of lipids, and to the multiplication and differentiation of monocytes into 
macrophage foam cells. Foam cells also produce cytokines and growth factors, 
further promoting atherosclerosis and are also postulated to serve as a source of 
matrix metalloproteinases, enzymes implicated in the weakening and rupture of 
the fibrous cap, the process thought to underlie most myocardial infarctions 
(Zandbergen and Plutzky, 2007). This characteristic lesion which consists of 
macrophage foam cells and T-cells, situated under a monolayer of endothelial 
cells, is the first lesion of atherosclerosis, the so called fatty-streak (Kaperonis et 
a/., 2006). 
In the fatty-streak lesion, T-cells are activated and together with native vascular 
wall cells, secrete cytokines (tumor necrosis factor-b, y-interferon), fibrogenic 
mediators and growth factors that can promote the migration and proliferation of 
smooth muscle cells {SMC) {Kaperonis eta/., 2006). SMC in the intima produce 
extracellular matrix components, including collagen, elastin and proteoglycans, 
which forms the fibrous cap and contributes to the stability of the plaque. This 
fibrous cap surrounds a lipid rich core in advanced plaques. SMC also 
synthesise proinflammatory cytokines including interleukin-1 (IL-1) and tumour 
necrosis factor-alpha (TNF-a). Gradually, the so called advanced atherosclerotic 
lesion is formed, with the characteristic core of lipids and necrotic tissue which is 
covered by a fibrous cap. 
3.2 Role of Biochemical Markers 
Biochemical markers play a pivotal role in the diagnosis and management of 
patients with ischemic heart disease (IHD). The World Health Organization 
{WHO) has traditionally defined Myocardial infarction as requiring the presence 
of at least two of three diagnostic criteria, namely, an appropriate clinical 
presentation, typical changes in the electrocardiogram and raised ~~cardiac" 
enzymes, essentially total creatine kinase {CK) or its MB iso-enzyme (CK-MB) 
activities {Panteghini, 2004). 
Consensus documents recently published by the European Society of 
Cardiology (ESC), the American College of Cardiology (ACC}, and the American 
Heart Association (AHA) make specific recommendations on the use of 
biomarkers for the detection of myocardial infarction (MI). The redefined criteria 
